Liver-led glycaemic control protein could be next T2D therapy

Victorian researchers have shown that a liver-secreted glucose-responsive protein, SMOC1, can decrease blood glucose levels and may be engineered as a potential treatment for people with type 2 diabetes. Published in  Science Translational Medicine, the study found that an engineered form of SMOC1 (sparc-related modular calcium-binding protein 1) improved blood sugar levels in animal models ...

Already a member?

Login to keep reading.

© 2021 the limbic